Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GW-833972A
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Oral
01
Overview
GW-833972A is a small-molecule inhibitor and degrader of BMAL2 (Basic Helix-Loop-Helix ARNT Like Effector 2), a circadian transcription factor. Identified through structure-based virtual screening, the compound effectively binds to BMAL2, leading to its degradation. In ovarian clear cell carcinoma (OCCC) models, BMAL2 inhibition by GW-833972A downregulates RAD51 and impairs homologous recombination-mediated DNA repair, thereby suppressing tumor growth and overcoming chemoresistance. The compound has demonstrated efficacy in suppressing tumor growth in vivo and is being investigated as a novel therapeutic strategy for chemoresistant ovarian cancers.
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on GW-833972A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GW-833972A.